Cetuximab biosimilar (Enzene Biosciences)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCetuximab biosimilar (Enzene Biosciences)

Drug Alias NameN/A

ClassificationBiologics > Biosimilar

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCarcinoma, Squamous Cell

Inactive IndicationsN/A

ATC CodeL01XC06